Market Newsdesk

SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) — Beam Global, (Nasdaq: BEEM, BEEMW), the leading provider of innovative sustainable technology for electric vehicle (EV) charging, outdoor media and energy security, announced today that a globally recognized entertainment franchise has deployed the EV ARC™ solar-powered EV charging system to cleanly charge EVs and power onsite production equipment.

The EV ARC™ system provides clean, quiet energy, replacing loud and polluting generators often used in remote filming locations. The systems are transportable and can be relocated as production sites change. Beam Global is proud to partner with the entertainment industry to enable on set cast and crew to Drive on Sunshine.

“This is the first use of EV ARC systems by the entertainment industry. However, we anticipate growth in the area following on the heels of the recent carbon emissions report from the Sustainable Production Alliance,” said Beam Global CEO Desmond Wheatley. “This global entertainment powerhouse is leading the industry in sustainability by providing clean and green power that deploys rapidly with no construction, no electrical work and no utility bill.”

The customer is a member of the Sustainable Production Alliance (SPA), a consortium of the world’s leading film, television, and streaming companies dedicated to advancing sustainability initiatives and reducing the entertainment industry’s overall environmental impact. On April 1, 2021 the SPA published the results from its Carbon Footprint Report, Close Up: Carbon Emissions of Film and Television Production, which made public for the first time industry-wide production carbon footprint averages for SPA’s member companies Amazon Studios, Amblin Partners, Disney, Fox Corporation, NBCUniversal, Netflix, Participant, Sony Pictures Entertainment, ViacomCBS and WarnerMedia, 2016 to 2019. The productions were shot in major filming cities around the world, and all used the Production Environmental Accounting Report (PEAR), created in partnership by SPA and the Producers Guild of America Foundation’s PGA Green committee. 

About Beam Global

Beam Global is a Cleantech leader that produces innovative, sustainable technology for electric vehicle (EV) charging, outdoor media, and energy security, without the construction, disruption, risks and costs of grid-tied solutions. Products include the patented EV ARC™ and Solar Tree® lines with BeamTrak™ patented solar tracking, and ARC Technology™ energy storage, along with EV charging, outdoor media and disaster preparedness packages.

The company develops, patents, designs, engineers and manufactures unique and advanced renewably energized products that save customers time and money, help the environment, empower communities and keep people moving. Based in San Diego, the company produces Made in America products. Beam Global is listed on Nasdaq under the symbols BEEM and BEEMW (formerly Envision Solar, EVSI, EVSIW). For more information visit https://BeamForAll.com/, LinkedIn, YouTube and Twitter.

Forward-Looking Statements

This Beam Global Press Release may contain forward-looking statements. All statements in this Press Release other than statements of historical facts are forward-looking statements. Forward-looking statements are generally accompanied by terms or phrases such as “estimate,” “project,” “predict,” “believe,” “expect,” “anticipate,” “target,” “plan,” “intend,” “seek,” “goal,” “will,” “should,” “may,” or other words and similar expressions that convey the uncertainty of future events or results.

Media Contact:
NextPR
[email protected]
+1-813-526-1195

CINCINNATI, May 11, 2021 (GLOBE NEWSWIRE) — Protech Home Medical Corp. (“Protech” or the “Company”) (TSXV:PTQ; OTCQX:PTQQF), a U.S. based leader in the home medical equipment industry, focused on end-to-end respiratory care, is pleased to announce that, subject to the receipt of all required regulatory approvals, including the approval of the TSX Venture Exchange (the “TSXV”), it intends to change its name to “Quipt Home Medical Corp.” (the “Name Change”) and consolidate its common shares (each, a “Common Share”) on the basis of one (1) post-consolidation Common Share for every four (4) pre-consolidation Shares (the “Share Consolidation”). The Name Change and Consolidation are anticipated to be completed on May 13, 2021 and it is expected that the Common Shares will commence trading on the TSXV on a post-Share Consolidation basis under the new name and new symbol “QIPT” on such date. The Name Change, symbol change and Share Consolidation are proposed to be completed in anticipation of the Company’s application to list the Common Shares on the NASDAQ Capital Market (“NASDAQ”).

The Company aims to set the standard of the home health industry and will be branded and utilized in local markets over time to meet the one-of-a-kind needs of every individual that puts their confidence in the name. Supported by the reach and the reputation of our current local brands, following the Name Change, the Company will continue to strive to enrich the lives of our patients by providing full-service technology-enabled home healthcare solutions to suit every kind of need, for every kind of patient.

The Company expects that on the same date that the Common Shares begin to trade on a post-Share Consolidation basis under the new name, its 8.0% unsecured convertible debentures due on March 7, 2024 (the “Debentures”) will commence trading on the TSXV under the new symbol “QIPT.DB.A”. No action will be required by existing holders of the Debentures with respect to the Name Change or Share Consolidation.

The CUSIP numbers assigned to the Common Shares and Debentures under its new name will be 74880P104 and 74880PAA2, respectively.

It is anticipated that Computershare Trust Company of Canada (“Computershare”) will mail letters of transmittal to the shareholders providing instructions on exchanging pre-Consolidation share certificates for post-Consolidation share certificates. At that time, shareholders are encouraged to send their share certificates, together with their letter of transmittal, to Computershare in accordance with the instructions in the letter of transmittal.

The Company is currently targeting to complete the proposed listing on NASDAQ by the end of June 2021, or as soon as possible thereafter, subject to satisfaction of all necessary listing requirements and acceptance of the Company’s Form 40-F Registration Statement by the United States Securities and Exchange Commission (the “SEC”). The Company will continue to trade under the symbol “PTQQF” on the OTCQX, following the Name Change and Share Consolidation and prior to completion of its proposed NASDAQ listing. While the Company intends to satisfy all of the applicable listing criteria, no assurance can be given that its application will be approved.

As previously disclosed in connection with the Company’s application for listing on the NASDAQ Capital Market, the Company’s auditor has concluded its review of the Q1, Q2 and Q3 of Fiscal 2020 financial statements for incorporation to the Form 40-F Registration Statement to be filed with the SEC. These restated and amended financial statements have been filed at www.sedar.com. For additional clarification, please note there has been no changes to the audited Fiscal Year-End 2020 financials as previously filed by the Company.

Management Commentary

“This represents a major milestone in the history of our Company, as we transform into Quipt Home Medical, readying for national expansion across the United States as a leader in respiratory homecare. Driven by our technology focused, patient-centric model, organic growth initiatives such as elevating our brand, combined with our acquisition plans has significantly widened our aperture of opportunity for our business,” said Greg Crawford, Chairman and CEO of Protech. “We feel timing our renaming process alongside our proposed NASDAQ listing will allow us to significantly garner awareness for our company in the United States. We expect to utilize Quipt as a brand over time in local markets, aiding in our robust organic growth strategy. Our interconnected healthcare platform is providing us much opportunity to gain market share and Quipt has all the resources needed to seize these opportunities. Additionally, I am pleased to report that our acquisition pipeline continues to be full, and we have a sustained focus on larger accretive transactions which further our goal of creating scale, and we look forward to keeping shareholders apprised as appropriate.”

ABOUT PROTECH HOME MEDICAL CORP.

The Company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company’s organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient’s services and making life easier for the patient.

Forward-Looking Statements

Certain statements contained in this press release constitute “forward-looking information” as such term is ‎‎‎defined in applicable Canadian securities legislation. The words “may”, “would”, “could”, “should”, “potential”, ‎‎‎‎”will”, “seek”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions as they relate ‎‎‎to the Company, including: governmental and TSXV approval of the proposed Name Change and Share Consolidation; the timing and completion of the proposed Name Change and Share Consolidation; the timing and completion of the proposed listing on NASDAQ; the filing and acceptance of the Form 40-F filing with the SEC, the Company anticipating to add additional locations either through organic opportunities or through inorganic opportunities; the Company expecting to derive strong revenue synergies from new locations organically; the Company’s plans to increase its footprint in current markets as well as adding new markets; the Company expecting to have further news on organic growth opportunities in the near future; and the Company expecting to be busy with new acquisitions in the near term; are intended to identify ‎forward-looking information. All statements other than ‎statements of ‎historical fact may be forward-looking ‎information. Such statements reflect the Company’s current ‎views and ‎intentions with respect to future events, and ‎current information available to the Company, and are ‎subject to ‎certain risks, uncertainties and assumptions , including: the Company successfully identified, negotiating and completing additional acquisitions, including accretive acquisitions. Many factors ‎could ‎cause the actual results, performance or achievements that may be expressed or ‎implied by such forward-‎looking ‎information to vary from those described herein should one or more of these risks ‎or uncertainties ‎materialize. ‎Examples of such risk factors include, without limitation: credit; market (including ‎equity, commodity, ‎foreign ‎exchange and interest rate); liquidity; operational (including technology and ‎infrastructure); ‎reputational; ‎insurance; strategic; regulatory; legal; environmental; capital adequacy; the ‎general business and ‎economic ‎conditions in the regions in which the Company operates; the ability of the ‎Company to execute on key ‎priorities, ‎including the successful completion of acquisitions, business retention, and ‎strategic plans and to ‎attract, develop ‎and retain key executives; difficulty integrating newly acquired businesses; ‎the ability to ‎implement business ‎strategies and pursue business opportunities; low profit market segments; ‎disruptions in or ‎attacks (including ‎cyber-attacks) on the Company’s information technology, internet, network ‎access or other ‎voice or data ‎communications systems or services; the evolution of various types of fraud or other ‎criminal ‎behavior to which ‎the Company is exposed; the failure of third parties to comply with their obligations to ‎the ‎Company or its ‎affiliates; the impact of new and changes to, or application of, current laws and regulations; ‎‎decline of ‎reimbursement rates; dependence on few payors; possible new drug discoveries; a novel business model; ‎‎‎dependence on key suppliers; granting of permits and licenses in a highly regulated business; the overall difficult ‎‎‎litigation environment, including in the U.S.; increased competition; changes in foreign currency rates; increased ‎‎‎funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds ‎‎‎and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, ‎‎‎and methods used by the Company; the occurrence of natural and unnatural catastrophic events ‎and claims ‎‎‎resulting from such events; and risks related to COVID-19 including various recommendations, orders ‎and ‎‎measures of governmental ‎authorities ‎to try to limit the pandemic, including travel restrictions, border closures, ‎‎‎non-essential business ‎closures, ‎quarantines, self-isolations, shelters-in-place and social distancing, disruptions ‎‎to ‎markets, economic ‎activity, ‎financing, supply chains and sales channels, and a deterioration of general ‎‎economic ‎conditions ‎including a ‎possible national or global recession‎; as well as those risk factors discussed or ‎‎referred to in ‎the Company’s disclosure ‎documents filed with the securities regulatory authorities in certain ‎‎provinces of Canada ‎and available at ‎www.sedar.com. Should any factor affect the Company in an unexpected ‎‎manner, or should ‎assumptions ‎underlying the forward-looking information prove incorrect, the actual results or ‎‎events may differ ‎materially ‎from the results or events predicted. Any such forward-looking information is ‎‎expressly qualified in its ‎entirety by ‎this cautionary statement. Moreover, the Company does not assume ‎‎responsibility for the accuracy or ‎‎completeness of such forward-looking information. The forward-looking ‎‎information included in this press release ‎is ‎made as of the date of this press release and the Company undertakes ‎‎no obligation to publicly update or revise ‎any ‎forward-looking information, other than as required by applicable ‎‎law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of ‎the ‎TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.‎

For further information please visit our website at www.protechhomemedical.com, or contact:

Cole Stevens
VP of Corporate Development
Protech Home Medical Corp.
859-300-6455
[email protected]

Gregory Crawford
Chief Executive Officer
Protech Home Medical Corp.
859-300-6455
[email protected]

HERNDON, Va., May 11, 2021 (GLOBE NEWSWIRE) — ManTech (Nasdaq: MANT) announced today that it has been awarded a contract to support the FBI with sophisticated technology solutions and expertise that deliver Information Systems Security, Management and Maintenance. The contract is for a base period of one year with the potential total performance period of five years if all options are exercised.

ManTech’s Cognitive Cyber, a key market differentiator, will support FBI cybersecurity stakeholders and help drive the mission of providing cybersecurity strategy, training and services for the FBI enterprise.

“In today’s world of high-tech criminals and terrorists, ManTech is excited to be selected as a trusted partner in providing sophisticated solutions that accelerate the ability to identify, stop and apprehend bad actors, and at the same time provide round-the-clock protection for vital IT systems and data,” said Bryce Pippert, Senior Vice President and General Manager of ManTech’s Federal Civilian Sector. “We are proud to support law enforcement in safeguarding national security on the home front.”

About ManTech

ManTech provides mission-focused technology solutions and services for U.S. defense, intelligence community and federal civilian agencies. In business more than 52 years, we excel in full-spectrum cyber, data collection & analytics, enterprise IT, systems engineering and software application development solutions that support national and homeland security. Additional information on ManTech can be found at www.mantech.com.

Media Contact:

Jim Crawford
ManTech
Executive Director, External Communications
(M) 571.446.7550
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1cbc097c-efe3-4fa1-8f4e-b97add86957f

VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) — Treatment.com International Inc. (“Treatment” or “The Company”) (CSE: TRUE) is an innovative healthcare technology company that is taking a unique consumer-centric approach to creating products that will disrupt the healthcare industry and help millions of people improve their health.

The healthcare industry has long relied on complex systems that leave the patients confused, overwhelmed and unsure of where to turn. As a result, consumers are demanding more visibility and control over their healthcare decisions, and Treatment.com is using technology to shift old systems and put power back into patients’ hands.

The Company spent over 5 years developing the smartest AI technology to think like a doctor. Knowing that the key to improved health outcomes is in empowering the consumer to make more informed health decisions, Treatment enlisted the help of Highland, a leading Chicago-based digital experience and product development firm, to conduct extensive consumer research to understand the needs and Jobs To Be Done in the healthcare industry.

“We spent a lot of time listening to what consumers said, and learned that healthcare is an emotional job. People want information, and they want to be supported and cared for. No one wants to feel like a statistic,” says Samantha Rayner, VP of Marketing for Treatment.com “With Highland, we used the Google Sprint model to rapidly prototype and test multiple iterations of our app and hear directly from the consumer what they wanted. This greatly influenced the direction we took for Cara, our new consumer product.”

David Whited, Director of Design Research and Strategy at Highland commented, “We were thrilled when the Treatment team came to us and said they wanted to gain the kind of deep motivational and behavioral insights that fuel the design of transformational digital experiences. We knew that Highland’s Jobs to Be Done research coupled with other exploratory research methodologies would deliver. We are grateful to have been able to play a role in the development of a product that will have such an enduring positive impact on consumer’s health journeys.”

Through the work with Highland, the Cara app was devised to focus on building a supportive relationship with the consumer first and provide simple tools that a busy caregiver can easily access to make better health decisions for their whole family.

Cara, the personal AI health assistant app launches in Canada summer 2021.

About Treatment.com

Treatment.com is a disruptive healthcare technology company that is harnessing the power of AI to help Canadians improve their health through personalized recommendations and insights. Based in Vancouver, the company spent the last five years working with a team of world-class doctors, engineers, mathematicians, and AI specialists to develop a complex AI engine that leverages the most robust, personalized data to generate highly predictive and accurate insights. Treatment.com is the parent company of Cara. This summer, Cara will be empowering Canadians to take control of their health with the launch of an innovative mobile app powered by this exclusive AI engine.

For more investor information on Treatment.com please visit https://treatment.com/investors/.

Forward Looking Statement

This news release contains forward-looking statements relating to the future operations of Treatment.com, International, Inc. (Treatment) and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of Treatment, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Treatment’s expectations include other risks detailed from time to time in the filings made by Treatment with securities regulators.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Treatment. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Treatment will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.

For more information:

Investor Contact: [email protected]